Identification of rat urinary metabolites of rifabutin using LC-MSn and LC-HR-MS

European Journal of Pharmaceutical Sciences

Volumn 41, Issue 1, 2010, Pages 173-188

  Prasad, Bhagwat ^a   Singh, Saranjit ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

LC MSn; Mass fragmentation; Metabolite identification; MetaSite; Rifabutin

Indexed keywords

DEUTERIUM; DRUG METABOLITE; HYDROGEN; RIFABUTIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG STRUCTURE; DRUG URINE LEVEL; HIGH RESOLUTION COMPUTER TOMOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RAT; SOLID PHASE EXTRACTION; ANIMAL; PROCEDURES; SPRAGUE DAWLEY RAT; URINE;

ANIMALS; ANTITUBERCULAR AGENTS; CHROMATOGRAPHY, LIQUID; MASS SPECTROMETRY; RATS; RATS, SPRAGUE-DAWLEY; RIFABUTIN;

EID: 77954763084     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.06.006     Document Type: Article

References (15)

1. Barluenga J., Aznar F., Garcia A.B., Cabal M.P., Palacios J.J., Menendez M.A. New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. 2006, 16:5717-5722.
2. Battaglia R., Salgarollo G., Zini G., Montesanti L., Benedetti M.S. Absorption, disposition, and urinary metabolism of 14C-rifabutin in rats. Antimicrob. Agents Chemother. 1991, 35:1391-1396.
3. Brogden R.N., Fitton A. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994, 47:983-1009.
4. Chen H., Chen Y., Du P., Han F. Structural elucidation of in vivo and in vitro metabolites of anisodine by liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2007, 44:773-778.
5. Figueiredo R., Moiteiro C., Medeiros M.A., da Silva P.A., Ramos D., Spies F., Ribeiro M.O., Lourenco M.C., Junior I.N., Gaspar M.M., Cruz M.E., Curto M.J., Franzblau S.G., Orozco H., Aguilar D., Hernandez-Pando R., Costa M.C. Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H(37)Rv. MDR and NRP Mycobacterium tuberculosis. Bioorg. Med. Chem. 2009, 17:503-511.
6. Giri S., Krausz K.W., Idle J.R., Gonzalez F.J. The metabolomics of (±)-arecoline 1-oxide in the mouse and its formation by human flavin-containing monooxygenases. Biochem. Pharmacol. 2007, 7:3561-3573.
7. Gjerde J., Kisanga E.R., Hauglid M., Holm P.I., Mellgren G., Lien E.A. Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 2005, 1082:6-14.
8. Iatsimirskaia E., Tulebaev S., Storozhuk E., Utkin I., Smith D., Gerber N., Koudriakova T. Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin. Pharmacol. Ther. 1997, 61:554-562.
9. Jamis-Dow C.A., Katki A.G., Collins J.M., Klecker R.W. Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica 1997, 27:1015-1024.
10. Kim I.H., Combrink K.D., Ma Z., Chapo K., Yan D., Renick P., Morris T.W., Pulse M., Simecka J.W., Ding C.Z. Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins. Bioorg. Med. Chem. Lett. 2007, 17:1181-1184.
11. Koudriakova T., Iatsimirskaia E., Tulebaev S., Spetie D., Utkin I., Mullet D., Thompson T., Vouros P., Gerber N. In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. J. Pharmacol. Exp. Ther. 1996, 279:1300-1309.
12. Prasad B., Singh S. In vitro and in vivo investigation of metabolic fate of rifampicin using an optimized sample preparation approach and modern tools of liquid chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 2009, 50:475-490.
13. Trapnell C.B., Jamis-Dow C., Klecker R.W., Collins J.M. Metabolism of rifabutin and its 25-desacetyl metabolite. LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole. Antimicrob. Agents Chemother. 1997, 41:924-926.
14. Utkin I., Koudriakova T., Thompson T., Cottrell C., Iatsimirskaia E., Barry J., Vouros P., Gerber N. Isolation and identification of major urinary metabolites of rifabutin in rats and humans. Drug Metab. Dispos. 1997, 25:963-969.
15. WHO Report Global tuberculosis control-epidemiology, strategy, financing (WHO/HTM/TB/2009.411) 2009, http://www.who.int/tb/publications/global_report/2009/en/.